Newsletter · · Ashutosh Agarwal

Pharma M&A Hits $150 Billion in H1, Led by Small Deals - The Biotech Patent Cliff & M&A - Week of July 10, 2026

Our synthesis of the biotech M&A podcast tape for the week of July 10, 2026. First-half pharma dealmaking hit close to $150 billion led by a drumbeat of smaller buys, Vertex wrote its largest-ever check for Crinetics, and Sanofi's policy head quantified the drug-pricing law's pill penalty steering the industry toward biologics.

The Biotech Patent Cliff & M&A

Week of July 10, 2026: Pharma M&A Hits $150 Billion in H1, Led by Small Deals

Last week the story was a thesis: biotech is cheap relative to the cash pharma throws off, so a takeout wave makes sense. This week the thesis showed up on the scoreboard. Pharma has now spent close to $150 billion buying companies in the first six months of 2026, the busiest half in years, and Vertex just wrote the biggest check in its history. The striking part isn't the size. It's that almost none of these are the giant, headline-grabbing "mega-deals." They're a steady drumbeat of $1-to-$13 billion buys. The cliff is real, the clock is running, and big pharma has stopped waiting.

TL;DR

  • The M&A supercycle is executing, not just being talked about. H1 2026 pharma M&A is running "close to $150 billion," on pace to top the 2019 record, and it's a high volume of smaller deals (biggest was ~$13B), not mega-mergers. Vertex bought endocrine specialist Crinetics for ~$10 billion, its largest-ever deal, at a big premium. Eli Lilly alone signed nine deals worth ~$25 billion.
  • The best hard number of the week explains why pharma keeps buying biologics. Sanofi's US policy head put a figure on the drug-pricing law's "pill penalty": for a small-molecule (pill) drug, being pulled into Medicare price negotiation four years earlier than a biologic wipes out "somewhere between 40% or 60% of the profit." The result: a 27% drop in new small-molecule cancer drugs. That's the tilt the deal machine is chasing.
  • The XBI is at all-time highs, and the traders who nailed the run are now saying "careful." Biotech ETFs have had "incredible moves" but look "a little bit high." Nobody's calling a top; a few are quietly refusing to chase.

What's new

The deals are printing, and $10 billion is the new sweet spot. The clearest tally came from the BioSpace team on "Vertex carries M&A uptick into H2, IPOs and VC raises also grow" (July 8). The week's marquee deal: Vertex's roughly $10 billion purchase of Crinetics Pharmaceuticals, an endocrine-disorder specialist, the largest acquisition in Vertex's history, and a notable move for a company that had stayed "laser focused" on cystic fibrosis. Vertex picks up an already-approved pill for acromegaly (a rare pituitary condition) plus a late-stage candidate for another rare hormonal disease, and says the two together could eventually deliver "over $5 billion in combined annual revenue." Stifel analysts called specialty endocrinology "emerging white space blockbuster opportunities." As the BioSpace editors put it, that $10 billion figure "seems to be the sweet spot for a lot of companies right now," it lines up neatly with the year's other big buys: AbbVie/Apogee at $10.7 billion and GSK/Nuvalent at $10.6 billion. (This is journalist/analyst framing, not operator commentary.)

Eli Lilly is in a category of its own. Same podcast: while Novartis, Gilead, and GSK have each done three deals this year, "Lilly has actually signed nine deals as of the end of the half, which totaled $25 billion." Lilly is the acquirer with the widest wallet and no near-term cliff of its own, the pace-setter everyone else is measured against.

Novartis makes a small, telling bet on the next wave of cancer drugs. On "Novartis' ADC gambit & regulation as catalyst for U.K. biotech" (July 7), the BioCentury team walked through Novartis buying private UK biotech Murex for $1.1 billion up front plus up to $400 million in milestones, its third deal of the year. Murex builds antibody-drug conjugates, or ADCs (think of them as a guided missile: an antibody that homes in on a tumor, carrying a toxic payload). What makes Murex unusual is the payload itself, a novel type most of the field isn't using. The company is a spin-out of Imperial College London and the Francis Crick Institute, and early backers Brandon Capital and Sofinnova Partners made "a handsome return." The strategic logic, per Novartis CEO Vas Narasimhan at a January investor conference: ADCs and bispecifics are "opportunities to build in oncology," an area where Novartis "has not done a lot of deals" recently. One early investor, Jonathan Tobin of Brandon Capital, called it "the biggest upfront for a preclinical asset in an acquisition," striking, given the drug hasn't yet been tested in humans. (Journalist reporting, with operator quotes sourced by the show.)

The single best number of the week: what the drug-pricing law is actually doing to the pipeline. This is the one that matters for the whole thesis. On the "What The IRA Means For Oncology Innovation" episode of the Vital Health Podcast (July 9), Michael Penn, US Head of Reimbursement and Public Policy at Sanofi, an industry insider, laid out fresh data (a Vital Transformation study presented at the big ASCO cancer conference) comparing the four years before and after the Inflation Reduction Act, the 2022 US law that lets Medicare negotiate prices on certain older drugs. The findings:

"We're seeing a 35% reduction in follow-on research, and we're seeing… a 27% reduction in lead assets in small molecule oncology."

The mechanism is what he calls the "pill penalty." The law lets Medicare start negotiating prices on ordinary pills (small molecules) after nine years, but waits thirteen for biologics (the big, complex, injected proteins). Those four extra years of protected pricing are enormous. In Penn's words:

"That nine-year pill penalty is somewhere between 40% or 60% of the profit goes away."

Lose 40-60% of the profit on your pills, and you stop making as many of them, hence the 27% drop in new small-molecule cancer programs. He also flagged that 2025 was "the second worst year" for the oncology pipeline since the law passed, undercutting the argument that the earlier slump was just the pandemic and high interest rates. This is the tilt underneath all the dealmaking: pharma is being pushed, by policy, toward biologics and large-population franchises, exactly the assets the M&A is chasing.

Meanwhile, the fundraising window is wide open. BioSpace noted a hair-loss biotech, Veridermix, up more than 650% since its February IPO (from $17 to about $128 a share) on an extended-release oral version of Rogaine, its CEO's pitch being that "obesity paved the way for hair loss," with the GLP-1 weight-loss boom as the playbook for selling directly to consumers. On the venture side, Isomorphic Labs raised a $2.1 billion round, "the second largest biotech raise of all time." Money is flowing in at every stage.

The debate

The podcasts this week were lopsided, heavily on the supercycle-bull side, with the caution coming mostly from chart-watchers rather than from anyone arguing the deals themselves are a mistake. Worth saying plainly: the "this will end in tears" case, FTC blocking deals, integration failures, overpaying at the top, was essentially not voiced this week. Domestic antitrust, in particular, remains a non-topic; no one is talking about the FTC as a threat to pharma M&A.

The bull case rests on the numbers above plus a genuine sentiment turn. On "Biotech euphoria driven by fundamentals" (July 8), Jonathan Faison, who runs the ROTY biotech community on Seeking Alpha, drew the contrast with the 2021 bubble, that peak was built on speculative IPOs "trying to raise money" before their drugs failed, whereas "much of the current optimism or euphoria is driven by fundamentals. The very, very heavy M&A appetite." His evidence: "Even within the last month, we saw three $10 billion plus buyouts with Nuvalent, Apogee and Krenetics." (Analyst/newsletter opinion.)

The clearest read on how far sentiment has flipped came from a veteran investor, "Lou," on Full Signal's "3 stocks Wall Street is IGNORING" (July 7). Big pharma is now "paying up in phase two to make acquisitions," early, before a drug is proven, whereas "24 months ago, no one would touch biotech," and something like "250, 300 biotech names… were trading below cash balances." Why the urgency? He put the cliff in one number:

"Big pharma has to replace by 2030… 180 billion in revenue from drugs that are going off patent… You can't do that just developing on your own. You got to go acquire it."

The caution, such as it was, came from the technical side, people who ride trends, now eyeing an overbought one. On The KE Report, TG Watkins of Simpler Trading said the biotech ETFs he trades "have had incredible moves. In fact, I called the ARCG move all the way back… in May," but added: "they are a little bit high. I don't know if you want to keep chasing those either." (July 7). His colleague-of-the-airwaves Joel Elconin was blunter on the ETF everyone watches: "The XBI, here's a trade I'd be careful of, a major leader, making a new all-time high today." (July 3). Note what this isn't: neither is arguing the fundamentals are broken. They're saying the price has run fast. That's a very different kind of worry than "this is a bubble."

The names in play

  • Vertex (VRTX), the buyer of the week. Its ~$10 billion Crinetics deal is the largest in company history and a deliberate step outside its cystic-fibrosis comfort zone into rare endocrine disease, with management guiding to "over $5 billion" in eventual peak sales from the assets. A perennial rumored acquirer finally acting.
  • Eli Lilly (LLY), nine deals, ~$25 billion, in six months. No cliff of its own, the deepest pockets in the group, and the benchmark every other acquirer is held against.
  • Novartis (NVS), three deals this year; the Murex buy is a cheap, early bet to build an ADC franchise in oncology after years of staying out. Watch whether the novel payload survives its first human trials.
  • Game Therapeutics (GANX), a speculative SMID idea from Full Signal's "Lou": an ~$100 million Parkinson's company (down ~40% this year) whose AI-discovered drug appeared to halt disease progression in a small early trial and "just got the nod in the last week to go into the phase 2 trial." His framing: "prime acquisition target… could easily be half a billion or a billion." His analog is Prevention Bio, which Sanofi bought after he'd owned it, "traded for two bucks a share and I got taken out at $26." High-risk, single-investor conviction; treat accordingly.

Read-throughs

  • Biosimilars, the puzzle finally got an explanation. Why do cheaper copies of blockbuster biologics keep failing to take share, even after a drug like Humira loses patent protection? On RealPharma's "Good Intentions, Bad Outcomes" (July 10), policy veteran Deborah Williams pinned it on the 340B hospital-discount program. After biosimilar competition arrived, AbbVie cut Humira's price to "penny priced," but inside 340B, hospitals still buy it "for a penny" and bill roughly "$7,000," pocketing the ~$6,999 spread, which incentivizes them to keep dispensing the brand over the cheaper copy. "Biosimilars have to be approved by the FDA… yet they have never really fulfilled the potential." The read-through for anyone underwriting a biosimilar maker's growth: the drag isn't clinical, it's the payment plumbing, and it isn't fixed yet.
  • XBI / SMID sentiment, hot, and rotating. The chart-watchers describe money rotating out of mega-cap tech and AI-semiconductors and into biotech, genomics, and financials, with CRISPR (CRSP) and NTLA singled out as breaking out. The XBI hitting all-time highs is the backdrop to every takeout conversation, but also the reason the technicians are getting twitchy.
  • Bankers and CROs, quiet again. No named contract-research organization (the outsourced labs that run drug trials) and no specific advisory-revenue thesis surfaced this week. A deal-a-week pace is obviously good for the banks, but nobody voiced it as a distinct call.

What changed

Last week the supercycle was an argument, a valuation case that biotech was a full turn of pharma cash flow cheaper than it was at the 2020 top, and a debate about whether the best biotechs (RevMed walking away from Merck) should even sell. This week it became a tally. The deals are closing: ~$150 billion booked in H1, Vertex writing its biggest-ever check, Lilly at nine deals and counting. The conversation moved from "should this happen and is it justified" to "look how much is already happening."

And there's a genuinely new piece of the puzzle. Last week the tilt toward biologics and big-population drugs was asserted (via the 2032 sales forecasts). This week Sanofi's own policy head quantified the cause, the 40-60% profit hit the pricing law lands on pills, and the 27% collapse in new small-molecule cancer programs it has already produced. That's not a market vibe; it's a policy-driven redirection of where the entire industry spends its research dollars, and it tells you exactly what kind of asset the deal machine will keep paying up for. The overhang to watch remains drug pricing (the IRA and the Most-Favored-Nation order), not the FTC, which, once again, nobody even mentioned.